Xeris Biopharma Holdings Inc
2B30
Company Profile
Business description
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USAT: +1 844 445-5704
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
394
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,241.24 | 85.01 | 1.04% |
| DAX 40 | 24,381.46 | 293.40 | 1.22% |
| Dow JONES (US) | 48,319.02 | 391.06 | 0.82% |
| FTSE 100 | 9,911.42 | 11.82 | 0.12% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,405.15 | 63.15 | -0.27% |
| Nikkei 225 | 51,063.31 | 220.38 | 0.43% |
| NZX 50 Index | 13,671.73 | 67.18 | 0.49% |
| S&P 500 | 6,855.23 | 8.62 | 0.13% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |